Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tolimidone - Melior Pharmaceuticals

Drug Profile

Tolimidone - Melior Pharmaceuticals

Alternative Names: CP-26154; MLR-1023; MTX-228

Latest Information Update: 12 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Melior Pharmaceuticals, Inc.
  • Developer Adhera Therapeutics; Bukwang Pharmaceutical; Melior Pharmaceuticals, Inc.
  • Class Antihyperglycaemics; Hepatoprotectants; Phenyl ethers; Small molecules
  • Mechanism of Action Lyn protein-tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Non-alcoholic steatohepatitis; Type 2 diabetes mellitus

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Preclinical COVID 2019 infections; Non-alcoholic steatohepatitis; Type 1 diabetes mellitus

Most Recent Events

  • 07 Feb 2024 Biodexa files for patent protection with US Patent and Trademark Office for Tolimidone in the US
  • 07 Feb 2024 Biodexa plans a phase Ia followed by phase IIb trial for Type 1 diabetes in 2024
  • 01 Jan 2024 Preclinical development in Non-alcoholic-steatohepatitis is still ongoing in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top